Literature DB >> 10699904

Expression of thymidine phosphorylase as an indicator of poor prognosis for patients with transitional cell carcinoma of the bladder.

J Arima1, Y Imazono, Y Takebayashi, K Nishiyama, T Shirahama, S Akiba, T Furukawa, S Akiyama, Y Ohi.   

Abstract

BACKGROUND: Thymidine phosphorylase (TP), which is identical to platelet-derived endothelial cell growth factor (PD-ECGF), stimulates chemotaxis of endothelial cells and is involved in the angiogenesis of human solid tumors.
METHODS: The activity and expression of TP were examined in human transitional cell carcinomas (TCCs) of the bladder, and their association with clinicopathologic findings was determined. The activity of the enzyme in 37 TCCs and 12 adjacent nonneoplastic tissues was measured spectrophotometrically. The expression of TP was also examined by immunoblotting. Immunohistochemical analysis was performed on 108 TCCs.
RESULTS: TP activity in the carcinomas was higher than that in adjacent normal tissues (P = 0.002). TP activity in Grade 3 tumors or those classified as pT2-4 was higher than in Grade 1 and 2 tumors (P = 0.017) or those classified as pT1 (P = 0.007). The level of expression of TP detected by immunoblotting correlated well with TP activity. Immunohistochemical analyses showed that 62 of 108 cases (57.4%) were TP positive. There was a significant correlation between TP expression and histologic grade, infiltration pattern, local invasion, and lymph node metastasis. TP expression as a prognostic variable was studied using the Cox proportional hazards model. TP overexpression was an independent prognostic factor, as were lymph node metastasis and local invasion.
CONCLUSIONS: These findings suggest that TP activity and its level of expression influence the progression of TCC and the prognoses of patients with this disease. Copyright 2000 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10699904

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  7 in total

1.  Thymidine phosphorylase influences [(18)F]fluorothymidine uptake in cancer cells and patients with non-small cell lung cancer.

Authors:  Seung Jin Lee; Jeong Seok Yeo; Haeng Jung Lee; Eun Jung Lee; Seog Young Kim; Se Jin Jang; Jong Jin Lee; Jin-Sook Ryu; Dae Hyuk Moon
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-02-22       Impact factor: 9.236

2.  Prognostic significance of thymidine phosphorylase in superficial bladder carcinoma.

Authors:  N E Stavropoulos; C Bouropoulos; E Ioachim; M Michael; K Hastazeris; I Tsimaris; D Kalogeras; Z Liamis; V Kafarakis; S Stefanaki; V Malamou-Mitsi
Journal:  Int Urol Nephrol       Date:  2005       Impact factor: 2.370

Review 3.  Current status and perspective of antiangiogenic therapy for cancer: urinary cancer.

Authors:  Shigeru Kanda; Yasuyoshi Miyata; Hiroshi Kanetake
Journal:  Int J Clin Oncol       Date:  2006-04       Impact factor: 3.850

4.  Cooperative stimulation of vascular endothelial growth factor expression by hypoxia and reactive oxygen species: the effect of targeting vascular endothelial growth factor and oxidative stress in an orthotopic xenograft model of bladder carcinoma.

Authors:  N S Brown; E H Streeter; A Jones; A L Harris; R Bicknell
Journal:  Br J Cancer       Date:  2005-05-09       Impact factor: 7.640

5.  Prognostic significance of thymidylate synthase in postoperative non-small cell lung cancer patients.

Authors:  Hong-Yun Zhao; Guo-Wei Ma; Ben-Yan Zou; Mei Li; Su-Xia Lin; Li-Ping Zhao; Ying Guo; Yan Huang; Ying Tian; Dan Xie; Li Zhang
Journal:  Onco Targets Ther       Date:  2014-07-16       Impact factor: 4.147

Review 6.  The dual role of thymidine phosphorylase in cancer development and chemotherapy.

Authors:  Annelies Bronckaers; Federico Gago; Jan Balzarini; Sandra Liekens
Journal:  Med Res Rev       Date:  2009-11       Impact factor: 12.944

7.  Proteomics analysis of bladder cancer invasion: Targeting EIF3D for therapeutic intervention.

Authors:  Agnieszka Latosinska; Marika Mokou; Manousos Makridakis; William Mullen; Jerome Zoidakis; Vasiliki Lygirou; Maria Frantzi; Ioannis Katafigiotis; Konstantinos Stravodimos; Marie C Hupe; Maciej Dobrzynski; Walter Kolch; Axel S Merseburger; Harald Mischak; Maria G Roubelakis; Antonia Vlahou
Journal:  Oncotarget       Date:  2017-04-20
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.